What Precigen (PGEN) Said on Its Q3 Earnings Call

Precigen (PGEN) reported Q3 earnings, highlighting growth indicators and $51M in cash. The company discussed competition, clinical data for PAPZIMEOS, and development plans. No Q4 revenue guidance was provided. Precigen expects to collect $96.5M in trade receivables and has access to additional borrowing capacity.

Original reporting

finance.yahoo.com

Published Nov 5, 2026, 5:14 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 5:25 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

What Precigen (PGEN) Said on Its Q3 Earnings Call — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

The call adds no new quantitative guidance, so market impact is expected to be muted.

Market read

Recap of already‑released earnings; limited trading relevance.

What to watch

Potential upcoming redosing study data in 2028 may be a longer‑term catalyst.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Precigen (NASDAQ:PGEN) provided commentary on its Q3 earnings, cash balance, debt capacity, and pipeline progress.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralHigh confidence

Context

Precigen discussed Q3 earnings call details, cash position and pipeline updates without new guidance or material data.

Expected impact

likely little movement as market has already priced Q3 results.

Evidence & confidence

The article repeats previously released Q3 numbers and adds no fresh financial metrics.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

Investors could view the cash buildup as a runway for future deals.

Key entities

company
Precigen
Clinical‑stage biotech focused on gene and cell therapies.

Read at source ← All news

$PGENMedAI 8/10

Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings

Precigen (PGEN) shares dropped 26% after Inovio (INO) received FDA approval for Voceryq, a rival to Precigen's Papzimeos. Voceryq offers easier dosing, though Papzimeos showed stronger trial results. Precigen reports Q3 earnings on November 4, with analysts expecting $236M in 2026 revenue.

finance.yahoo.comNov 2

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

finance.yahoo.comNov 2

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.comOct 30

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

insidermonkey.comSep 29

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

prnewswire.comSep 21

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.comAug 21